{"schema_version":"1.0","type":"article","title":"胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.md","lang":"zh-Hant","date":"2026-06-27","publish_at":"2026-06-27T10:30:00+08:00","updated_at":"2026-06-27","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","胰臟癌","RAS","PRMT5","MAT2A","臨床數據","生技投資","BD"],"summary":"胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。","key_points":[],"facts":[],"sections":["01｜為什麼 Vopimetostat + Daraxonrasib 這麼震撼？","02｜安全性是關鍵：療效漂亮，但劑量訊號要看仔細","03｜IDEAYA 也出手：PRMT5 賽道開始拚「誰更精準」","04｜MAT2A 是第三塊拼圖：RAS + PRMT5 + MAT2A 的三聯想像","05｜PRMT5／MAT2A 賽道正在變熱，大型藥廠不會缺席","結語｜胰臟癌正在從化療時代，走向精準聯合療法時代"],"references":[{"title":"[0] 各公司官網與公開資料：Revolution Medicines、Tango Therapeutics、IDEAYA Biosciences。","source":"","date":"","url":""},{"title":"[1] PubMed","source":"Daraxonrasib / RASolute-302 相關研究：","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/42223072/"},{"title":"[2] Tango Therapeutics","source":"PRMT5 program overview：","date":"","url":"https://www.tangotx.com/programs/prmt5/"},{"title":"[3] Investor's Business Daily","source":"Tango Therapeutics / Revolution Medicines combination data coverage：","date":"","url":"https://www.investors.com/news/technology/tango-therapeutics-tngx-stock-revolution-medicines-rvmd-stock-pancreatic-cancer/"},{"title":"[4] IDEAYA Biosciences","source":"IDE892 initiates Phase 1/2 clinical combination study in MTAP-deleted pancreatic and lung cancers：","date":"","url":"https://ir.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers"},{"title":"[5] IDEAYA Biosciences","source":"First patient in for Phase 1 trial of IDE892 and MTAP/CDKN2A pipeline update：","date":"","url":"https://ir.ideayabio.com/2026-03-09-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE892,-a-Potential-Best-In-Class-PRMT5-Inhibitor-for-MTAP-Deleted-Solid-Tumors,-and-Provides-MTAP-and-CDKN2A-Pipeline-Update"}],"images":[{"alt":"Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 1）","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-01.png"},{"alt":"Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 2）","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-02.png"},{"alt":"Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 3）","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-03.png"},{"alt":"Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 4）","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-27）。胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開。https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}